Auricular acupuncture, recommended by the World Health Organization (WHO) and offered as an integrative practice since 2006 by the SUS (Sistema Única de Saúde), Brazil’s national health service, is safe for patients with depression and effectively reduces symptoms of this mental health disorder, according to a study conducted by researchers at the University of São Paulo (USP) and the University of Southern Santa Catarina (UNISUL).
The results of the study are reported in an article published in the journal JAMA Network Open. They confirm the efficacy of auricular acupuncture as an alternative treatment for depression, a mood disorder for which rising numbers are seeking care from the SUS, judging from data provided by the Ministry of Health.
Depression is one of the leading causes of disability worldwide, according to the WHO. In Brazil, the lifetime prevalence of depression is 15.5%, one of the highest globally, and depressive disorders account for 10.3% of years of life lost (YLL), a measure of premature mortality calculated by subtracting the age at death from the longest possible life expectancy for a person at that age.
Professor Dario Floreano is a Swiss-Italian roboticist and engineer engaged in a bold research venture: the creation of edible robots and digestible electronics.
However counterintuitive it may seem, combining food science and robotic science could yield enormous benefits. These range from airlifts of food to advanced health monitoring.
Strategies differ, but there are some gene edits that all researchers agree must underpin any universal stem-cell-derived therapy. There is also widespread consensus that the optimal product should incorporate as few edits as possible, both to minimize the potential for unintended genetic consequences and to streamline manufacturing and regulatory approval.
Beyond that, the scientific community is divided. The complexities of the immune system have fuelled spirited debates over the exact genetic manipulations necessary to create a cell therapy that is both capable of bypassing immune defences and delivering meaningful health benefits.
“The immune system is pervasive and persistent,” says Charles Murry, a cardiovascular pathologist at the University of Washington in Seattle and chief executive of StemCardia in Seattle, one of a growing number of biotechnology companies developing gene-editing strategies to overcome immune barriers in regenerative cell treatments.
“Cannabis use is increasing in both prevalence and frequency, while conventional tobacco smoking is declining,” said Salomeh Keyhani, MD, MPH. “Cannabis use by itself might, over time, become the more important risk factor.”
Can smoking cannabis bring the same risk of heart attack and stroke as smoking cigarettes? This is what a recent study published in the Journal of the American Heart Association hopes to address as a team of researchers from the University of California, San Francisco (UCSF) investigated the likelihood that cannabis use would lead to a heart attack and/or stroke. This study comes as recreational cannabis use is slowly becoming legal across the United States and holds the potential to help researchers, medical professionals, legislators, and the public better understand the long-term health risks associated with cannabis use, specifically smoking cannabis.
For the study, the team compared data from the Behavioral Risk Factor Surveillance Survey between 2016 and 2020 across 27 American states and 2 territories and 434,104 survey participants between ages 18 and 74 to ascertain a link between their cannabis use and likelihood for heart problems. The team classified cannabis use as the number of times a participant smoked cannabis within a previous 30 days while accounting for self-reported heart issues and tobacco use, as well.
In the end, the team found that 4 percent of participants use cannabis daily while 7.1 percent did not. When combined with the self-reported heart issues of the daily cannabis users, the team found this group exhibited a 25 percent chance of having a heart attack and a 42 percent chance of having a stroke.
Elon Musk claims OpenAI is using GPT-4 to ‘maximize profits’ instead of ‘for the benefit of humanity.’
The lawsuit claims that the GPT-4 model OpenAI released in March 2023 isn’t just capable of reasoning but is also actually “better at reasoning than average humans,” having scored in the 90th percentile on the Uniform Bar Examination for lawyers. The company is rumored to be developing a more advanced model, known as “Q Star,” that has a stronger claim to being true artificial general intelligence (AGI).
Altman was fired (and subsequently rehired five days later) by OpenAI in 2023 over vague claims that his communication with the board was “hindering its ability to exercise its responsibilities.” The lawsuit filed by Musk alleges that in the days following this event, Altman, Brockman, and Microsoft “exploited Microsoft’s significant leverage over OpenAI” to replace board members with handpicked alternatives that were better approved of by Microsoft.
“The new Board members lack substantial AI expertise and, on information and belief, are ill equipped by design to make an independent determination of whether and when OpenAI has attained AGI — and hence when it has developed an algorithm that is outside the scope of Microsoft’s license,” claims the lawsuit. The partnership between OpenAI and Microsoft is currently being examined by regulators in the UK, EU, and US to assess if their shared relationship impacts competition.
A team of Stanford Medicine doctors and biomedical engineers are among the first to integrate a new augmented reality tool into surgical practice. The technology, Apple Vision Pro, is a headset that provides a form of human-computer interaction — it allows its wearer to navigate their surroundings using real-time visual data in combination with virtual elements.
“The novel use of augmented reality in the operating room exemplifies Stanford Medicine’s mission of serving patients in a digitally driven, human-centered care environment,” said Lloyd Minor, dean of the School of Medicine and vice president of medical affairs at Stanford University. “Our health system has long stood at the vanguard for the use of digital technologies in medicine, and I’m proud that through initiatives like RAISE Health, we also define the safe, responsible and equitable use of these innovations.”
A cardiologist used the technology, with the patient’s informed consent, to successfully perform an ablation procedure this week at Stanford Hospital to treat atrial fibrillation.
Researchers at the National Institutes of Health have identified antibodies targeting a hard-to-spot region of the influenza virus, shedding light on the relatively unexplored “dark side” of the neuraminidase (NA) protein head. The antibodies target a region of the NA protein that is common among many influenza viruses, including H3N2 subtype viruses, and could be a new target for countermeasures. The research, led by scientists at the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center, part of NIH, was published today in Immunity.
Influenza, or flu, sickens millions of people across the globe each year and can lead to severe illness and death. While vaccination against influenza reduces the burden of the disease, updated vaccines are needed each season to provide protection against the many strains and subtypes of the rapidly evolving virus. Vaccines that provide protection against a broad range of influenza viruses could prevent outbreaks of new and reemerging flu viruses without the need for yearly vaccine reformulation or vaccinations.
One way to improve influenza vaccines and other countermeasures is to identify new targets on the virus’s surface proteins in “conserved” regions—portions that tend to be relatively unchanged between different strains of the virus. Influenza NA is a surface protein containing a globular head portion and a narrow stalk portion.
Interestingly enough, although Elon Musk’s Neuralink received a great deal of media attention, early in 2023, Synchron published results from its first-in-human study of four patients with severe paralysis who received its first-generation Stentrode neuroprosthesis implant. The implant allowed participants to create digital switches that controlled daily tasks like sending texts and emails, partaking in online banking, and communicating care needs. The study’s findings were published in a paper in JAMA Neurology in January 2023. Then, before September, the first six US patients had the Synchron BCI implanted. The study’s findings are expected by late 2024.
Let’s return to Upgrade. “One part The Six Million Dollar Man, one part Death Wish revenge fantasy” was how critics described the movie. While Death Wish is a 1974 American vigilante action-thriller movie that is partially based on Brian Garfield’s 1972 novel of the same name, the American sci-fi television series The Six Million Dollar Man from the 1970s, based on Martin Caidin’s 1972 novel Cyborg, could be considered a landmark in the context of human-AI symbiosis, although in fantasy’s domain. Oscar Goldman’s opening line in The Six Million Dollar Man was, “Gentlemen, we can rebuild him. We have the technology. We have the capability to make the world’s first bionic man… Better than he was before. Better—stronger—faster.” The term “cyborg” is a portmanteau of the words “cybernetic” and “organism,” which was coined in 1960 by two scientists, Manfred Clynes and Nathan S Kline.
At the moment, “cyborg” doesn’t seem to be a narrative of a distant future, though. Rather, it’s very much a story of today. We are just inches away from becoming cyborgs, perhaps, thanks to the brain chip implants, although Elon Musk perceives that “we are already a cyborg to some degree,” and he may be right. Cyborgs, however, pose a threat, while the dystopian idea of being ruled by Big Brother also haunts. Around the world, chip implants have already sparked heated discussions on a variety of topics, including privacy, the law, technology, medicine, security, politics, and religion. USA Today published a piece headlined “You will get chipped—eventually” as early as August 2017. And an article published in The Atlantic in September 2018 discussed how (not only brain chips but) microchip implants, in general, are evolving from a tech-geek curiosity to a legitimate health utility and that there may not be as many reasons to say “no.” But numerous concerns about privacy and cybersecurity would keep us haunted. It would be extremely difficult for policymakers to formulate laws pertaining to such sensitive yet quickly developing technology.
Professor Nadeem Sarwar is Corporate Vice President, Co-Founder and Head, Transformational Prevention Unit, Novo Nordisk (https://www.novonordisk.com/partnerin…), Co-Chair UK Dementia Mission (a UK Government Ministerial appointment) and Honorary Professor, University of Edinburgh Medical School.
Professor Sarwar joined Novo Nordisk in June 2023 as Corporate Vice President, Co-Founder and Head of Novo Nordisk’s new Transformational Prevention Unit (TPU) whose mission is to increase obesity-free life years, so people live healthier and longer lives. To achieve this, the TPU is establishing an integrated ecosystem that will deliver science-first, empowering, and scalable commercial solutions that predict and pre-empt obesity and its consequences through innovative partnerships, with solutions intending to push the boundaries of what is possible with drugs, genomics, microbiome, digital health, and behavioral science.
Professor Sarwar’s expertise stems from scientific and business models at the intersection of genomics, data sciences and digital technologies for therapeutic and health innovation and he utilizes this expertise to steer the strategy and implementation of the predictive and pre-emptive obesity solutions being developed by the TPU, spanning both R\&D and commercial strategy.
Professor Sarwar joins Novo Nordisk with extensive executive experience in academia (Cambridge, Edinburgh), pharma (Pfizer, Eisai, Novo Nordisk), biotech (Genetics Guided Demantia Discovery — G2D2), company incubation (Eisai Innovation Biolabs), and government (UK Dementia Mission). He has successfully built and led organizations across the UK, US, Japan, and Denmark; and contributed to delivery of therapeutics into clinical trials for cardiometabolic diseases, oncology, SLE, COVID-19 and neurodegeneration.
Professor Sarwar’s research has been published in leading medical journals (eg, NEJM, Lancet, JAMA), presented at international meetings (eg, American Diabetes Association; World Dementia Council), and profiled by international media (eg, BBC, Forbes). He has provided expert insights for the UK Department of Health, the World Economic Forum, and the US National Academies of Sciences.
Apart from his current position at Novo Nordisk, Professor Sarwar holds the position of Honorary Professor at the University of Edinburgh Medical School. He also currently serves on the UK Medical Research Council (MRC) Neuroscience and Mental Health Board, the UK MRC Prevention Task and Finish Group, the Health Data Industry Expert Sub-Group, and the UK Life Sciences Council.
